Cerecor Inc. (CERC) Stock

About Cerecor Inc.

Cerecor Inc. operates as a biopharmaceutical firm dedicated to the discovery and marketing of therapeutic solutions, primarily addressing rare pediatric and orphan diseases. The company maintains an active pipeline, including: Inherited Metabolic Disorders: Advancing CERC-801 and CERC-802, both of which have successfully completed Phase I clinical trials, alongside CERC-803. Autoimmune Inflammatory Conditions: Developing CERC-007, an anti-IL-18 monoclonal antibody, designed to combat ailments such as adult-onset Still's disease and multiple myeloma. Complex Lymphatic Malformations: Progressing CERC-006, a dual mTOR inhibitor. Pediatric-onset Crohn's Disease: Working on CERC-002, an anti-LIGHT monoclonal antibody. Mitochondrial Disorders: Investigating CERC-913, a protide nucleotide. Rare Auto-inflammatory Diseases: Developing CERC-005, a monoclonal antibody. Symptomatic Orthostatic Hypotension: Pursuing CERC-301. Parkinson's Disease: Researching CERC-406. Beyond its research and development efforts, Cerecor also markets Millipred, an oral prednisolone formulation used to manage various inflammatory ailments. These include conditions affecting the joints (arthritis), blood, immune system, skin, eyes, respiratory system, as well as certain cancers and severe allergies. Established in 2011, when it rebranded from Ceregen Corporation to Cerecor Inc., the company's headquarters are situated in Rockville, Maryland.

Cerecor Inc. is headquartered in US.

Cerecor Inc. (CERC) stock trades at $2.93 with a market capitalization of $38.63M. The stock is valued at a price-to-earnings (P/E) ratio of -0.53, price-to-book of 0.86, price-to-sales of -184.83. Over the past 52 weeks the stock has ranged between $1.98 and $4.50, and currently trades 34.9% below its 52-week high.

On profitability, Cerecor Inc. generates a return on equity (ROE) of -112.68%, return on capital employed of -89.66%.

Official website: www.cerecor.com